ClinicalTrials.gg
CompletedNCT01529944Updated Aug 9, 2023

Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658

A Phase 3 interventional study of somatropin and somatropin in Genetic Disorder and Noonan Syndrome, sponsored by Novo Nordisk A/S. Completed at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S — none open to participants now, 2 under way, 2 of them phase 3. Genetic Diseases, Inborn · Novo Nordisk A/S.

Enrollment
15th of 15
22 · median 51
Started
2008
with 1 other
Phase 3
8 of 23
none open now
Registered
7th of 23
by date

Among the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S, this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2008, is one of 8 in phase 3, and was the 7th registered.

Genetic Diseases, Inborn

584 studies on the registry are indexed under Genetic Diseases, Inborn; 158 are open to participants now.

Browse Genetic Diseases, Inborn studies →

Open to participants now

None of the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S is open now. The open studies under Genetic Diseases, Inborn, anywhere →

Who these studies take

Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data obtained in the GHNOO-1658 trial.

03

Conditions studied

  • Genetic Disorder
  • Noonan Syndrome
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Participation in the GHNOO-1658 trial
  • Subject has completed genetic testing of PTPN11 mutation
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Low dose 33 mcg/kg/day

    Drug: somatropin

  • Experimental
    High dose 66 mcg/kg/day

    Drug: somatropin

Interventions

  • Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.

  • Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.

06

What researchers measure

Primary outcomes

  1. Change in height SDS (Standard Deviation Score) (referenced to normal population)

    Time frame: From baseline until final height is reached

Secondary outcomes

  1. Final height SDS (referenced to normal population)

    Time frame: From baseline until final height is reached

  2. Final height SDS (referenced to Noonan population)

    Time frame: From baseline until final height is reached

  3. Change in height SDS (referenced to Noonan population)

    Time frame: From baseline until final height is reached

  4. Number of subjects with final height SDS above - 2SDS (reference to normal population)

    Time frame: When final height is reached

  5. Proportion of subjects with final height SDS above - 2SDS (reference to normal population)

    Time frame: When final height is reached

  6. Adverse events

    Time frame: From baseline until final height is reached

07

Study locations

1 site
  • Göteborg, 416 85, Sweden
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2012
First posted
Feb 9, 2012
Start
Sep 2008
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Last update
Aug 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01529944
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 9, 2012
Start date
Sep 2008
Primary completion
Oct 2008
Completion
Oct 2008
Last update
Aug 9, 2023

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion